| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Vlocity, a Forbes Cloud 100 company and strategic Salesforce ISV, delivers industry-specific cloud and mobile software that embed digital, omnichannel processes for customer-centric industries.
Flow is a fast, secure, and developer-friendly blockchain built to support the next generation of games, apps, and the digital assets that power them.
Caffeine is a social broadcasting platform for gaming, entertainment, and the creative arts. With Caffeine you can engage in real-time with the broadcaster or your viewers.
Shockoe is a company that specializes in mobile app development and digital experiences. They provide full-service solutions for a variety of industries, from inventory and asset management to mobile workforce and customer loyalty.